Meet with… Dementia Discovery Fund
JLABS @ LabCentral , 700 Main Street, North , Cambridge , MA 02139
January 23, 2018 from 11:30 AM to 14:00 PM (EST)
$10 - $35
Dementia is arguably the greatest single global healthcare challenge, affecting more than 47 million people worldwide at an estimated annual cost to the global economy of over US $604 billion. Despite the increasing scale of the problem, research has not produced any disease modifying treatments, with current therapies limited to symptomatic treatments, having no effect on underlying disease. The Dementia Discovery Fund (“DDF”) is a highly innovative new fund backed by the UK Government, Alzheimer’s Research UK and seven of the world’s leading pharmaceutical and biotech companies.
The DDF is funding the discovery and development of new disease-modifying treatments for Alzheimer’s and other forms of dementia with the intent to improve dramatically the quality of life for the growing number of dementia sufferers and their families while also generating a financial return.
Barbara Tate, Venture Partner, DDF will be in attendance to present an overview of the DDF, key areas of interest and investment models. Following the presentation, she will be on hand to meet with a handful of approved applicants one-on-one after the presentation. The application period has ended.
10:30am | Registration Opens & Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. The application period has ended.
DDF Participating Representative:
Barbara Tate | Venture Partner, Dementia Discovery Fund
Dr. Barbara Tate is a neuroscientist who has worked in both large and small pharmaceutical companies. Prior to joining DDF, she was Vice President and Head of Biology at Rodin Therapeutics, an Atlas Venture company, where she also consulted on other portfolio companies. Prior to Rodin, Barbara was Vice President for Research at Satori Pharmaceuticals, a biotech company developing a treatment for Alzheimer’s disease. At Pfizer, Barbara managed the neurodegenerative disease area group in Groton, CT. Prior to working in industry, Barbara was an academic researcher at Brown Medical School and Harvard Medical School. Barbara has a BA in Biology, a PhD in Physiology, and she was a postdoctoral fellow at Harvard Medical School.
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to January 23 (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The application period has ended.
700 Main Street, North
Cambridge, MA 02139
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Welcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
About the Dementia Discovery Fund:
The DDF will invest in innovative projects and companies exploring novel biological mechanisms that have the potential for transformational clinical impact, and not follow the well-trodden path of amyloid beta interventions. The DDF collaborates closely with its outstanding international Scientific Advisory Board, composed of highly experienced neuroscientists from leading biotech and pharma companies Biogen, GSK, Johnson & Johnson, Lilly, Pfizer, Astex and Takeda, the charity ARUK, and other experts in the dementia field. The DDF will invest at an early stage, as well as in companies that are closer to the clinic, with investment team members in both the US and the UK. To date, the DDF has invested in both companies and projects, including Alector, an immuno-neurology focused biotech, Cerevance, a new platform company identifying novel targets in human brain tissue, as well as a collaborative project with Autifony, an established biotech company working in hearing loss, but with an interest in developing the rationale across similar target space but for dementia.